Menu
Recruiting NCT03770936

Effect of Some Drugs on Liver Fibrosis

Phase III Interventional Liver Fibroses

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Candesartan, Ramipril.
Who it may be relevant to
Registry conditions: Liver Fibroses. Basic parameters: from 20 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C

Overview

Effect of Some Drugs on Liver Fibrosis

Detailed description

The study aimed at evaluating the effect of Some Drugs on Liver Fibrosis

Interventions

  • Drug Candesartan
    Candesartan 8 mg/day
  • Drug Ramipril
    ramipril 1.25 mg/day

Primary outcome measures

  • Change in Fibroscan or APRI score [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • chronic hepatitis C

Exclusion criteria

  • Acute hepatitis
  • Thalassemia

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Sherief Abd-Elsalam — Tanta

Publications

  • Mostafa TM, El-Azab GA, Badra GA, Abdelwahed AS, Elsayed AA. Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study. Curr Ther Res Clin Exp. 2021 Nov 12;95:100654. doi: 10.1016/j.curtheres.2021.100654. eCollection 2021. PMID 34925649

Identifiers

NCT: NCT03770936 · liver fibrosis

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗